Prestige And Pharmapark Add Bevacizumab To Russia Collaboration
Commercialization Agreement Signed In 2019 Over Herceptin Biosimilar
Russia’s Pharmapark has added Prestige BioPharma’s HD204 biosimilar bevacizumab product to the firms’ commercialization partnership, two years after kicking off the partnership with trastuzumab.
You may also be interested in...
Prestige And Intas Strike International Bevacizumab Deal
Prestige Biopharma and Intas Pharmaceuticals have announced a commercialization deal for Prestige’s HD204 proposed bevacizumab biosimilar, covering a range of territories including markets in the Americas, Europe, Africa and Asia.
Dr Reddy’s To Market Prestige's Trastuzumab Across Latin America And Southeast Asia
Prestige BioPharma has made the latest commercialization partnership for its proposed trastuzumab biosimilar, with Dr Reddy’s now in place to market the drug across select nations in Latin America and Southeast Asia.
Prestige Plans ‘Strong Price Competitiveness’ For Its Adalimumab Biosimilar
As Prestige BioPharma announced plans for Phase I and Phase III trials of its PBP1502 proposed adalimumab biosimilar, as well as expected filing dates in the EU and US, the company outlined how it believes its proprietary technology will allow its Humira rival to compete aggressively on price.